C4 Therapeutics, Inc. (CCCC)
NasdaqGS · USD · Healthcare · Biotechnology
$2.98 (-2.61%) as of
Key statistics
- Market cap
- 366.61M
- Forward P/E
- -3.10
- EPS (TTM)
- -0.8900
- Dividend yield
- 0.00%
- 52-week range
- 1.6900 – 5.1700
- Beta
- 3.08
- Revenue (TTM)
- 35.04M
- Profit margin
- -289.44%
- Analyst target
- $12.86
- Volume
- 3.18M
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Watertown, MA, United States
- Employees
- 104
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.